The global Minimal Residual Disease (MRD) market size was USD 1,095.3 Million in 2021 and is expected to register a revenue CAGR of 16.04% during the forecast period, according to the latest analysis by Emergen Research. Rising R&D activities and increase in research funding from various cancer institutes are major factors projected to support market revenue growth between 2021 and 2030. For instance, Invitae Corporation, based in the U.S., started a research in February 2022 to collect actual data on tailored minimal residual disease diagnostics for distinct tumor types. Inivata also introduced RaDaR assay in April 2020 to identify and track residual disease and relapse in plasma samples of patients with prior cancer diagnoses. In addition, RaDaR assay is based on next-generation sequencing platform InVision liquid biopsy, developed by Inivata, which has built-in control and error checking for highly sensitive and precise variant detection. Moreover, to improve testing and detection outcomes, companies competing in the worldwide MRD testing market are concentrating more on disease-specific and tailored diagnostic kits, which is also expected to drive revenue growth of the market.
The report also covers an in-depth analysis of the key competitors of the market along with their growth strategies and business expansion plans. Further offers a comprehensive coverage of the strategic alliances such as mergers and acquisitions, joint ventures, collaborations, product launches, brand promotions, and partnerships, among others. Key strategic alliances for product development and advancements is expected to add traction to market growth going ahead. The report also covers an in-depth analysis of the key competitors of the market along with their growth strategies and business expansion plans.
Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/1352
Competitive Terrain:
The global Minimal Residual Disease industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.
The leading market contenders listed in the report are:
Adaptive Biotechnologies, ARUP Laboratories, Bio-Rad Laboratories, Inc., Cergentis B.V., F. Hoffmann-La Roche Ltd., ICON Plc, Invivoscribe, Inc., Laboratory Corporation of America Holdings, Mission Bio, Natera, Inc., NeoGenomics Laboratories, OPKO Health, Inc., and Sysmex Corporation
Key market aspects studied in the report:
Market Scope: The report explains the scope of various commercial possibilities in the global Minimal Residual Disease market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.
Competitive Outlook: The leading companies operating in the Minimal Residual Disease market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.
Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Minimal Residual Disease market.
Market Segmentations of the Minimal Residual Disease Market
This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Minimal Residual Disease market on the basis of product, application, and region:
Segments Covered in this report are:
-
Indication Outlook (Revenue, USD Million; 2019–2030)
- Leukemia
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Lymphoblastic Leukemia (CLL)
- Acute Myeloid Leukemia (AML)
- Chronic Myeloid Leukemia (CML)
- Others
- Lymphoma
- Non-Hodgkin’s Lymphoma (NHL)
- Marginal Zone Lymphoma
- Follicular Lymphoma
- Peripheral T-cell Lymphoma
- Mantle Cell Lymphoma
- Others
- Multiple Myeloma (MM)
- Solid Tumor
- Others
- Leukemia
-
Detection Outlook (Revenue, USD Million; 2019–2030)
- Next-Generation Sequencing (NGS)
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Fluorescence In-Situ Hybridization (FISH)
- Others
-
Treatment Methods Outlook (Revenue, USD Million; 2019–2030)
- Chemotherapy
- Stem Cell Transplant
- CAR-T Cell Therapy
- Others
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/minimal-residual-disease-market
Major Geographies Analyzed in the Report:
- North America (U.S., Canada)
- Europe (U.K., Italy, Germany, France, Rest of EU)
- Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
- Latin America (Chile, Brazil, Argentina, Rest of Latin America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
ToC of the report:
Chapter 1: Market overview and scope
Chapter 2: Market outlook
Chapter 3: Impact analysis of COVID-19 pandemic
Chapter 4: Competitive Landscape
Chapter 5: Drivers, Constraints, Opportunities, Limitations
Chapter 6: Key manufacturers of the industry
Chapter 7: Regional analysis
Chapter 8: Market segmentation based on type applications
Chapter 9: Current and Future Trends
About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
